Statistics from Altmetric.com
We read with great interest, the recent article titled ‘Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies’ by Chen and colleagues published online in July in Gut.1 In this large, population-based, case-control study using the Taiwanese National Health Insurance Research Database, they reported that in patients with diabetes mellitus (DM), metformin use is associated with a decrease in the risk of hepatocellular cancer (HCC) in a dose- and duration-dependent manner. Metformin users had a 21% lower risk of HCC on multivariate stratified analysis, after adjusting for potential confounders (age, gender, hepatitis B, hepatitis C, liver cirrhosis, DM duration and antidiabetic therapy). …
Contributors Both authors have contributed equally to the drafting of this letter.
Competing interests None.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.